Skip Navigation LinksHome > June 2013 - Volume 20 - Issue 6 > Estrogen alone and joint symptoms in the Women’s Health Init...
Menopause:
doi: 10.1097/GME.0b013e31828392c4
Original Articles

Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial

Chlebowski, Rowan T. MD, PhD1; Cirillo, Dominic J. MD, PhD2; Eaton, Charles B. MD3; Stefanick, Marcia L. PhD4; Pettinger, Mary MS5; Carbone, Laura D. MD, MS6; Johnson, Karen C. MD, MPH7; Simon, Michael S. MD, MPH8; Woods, Nancy F. PhD, RN, FAAN9; Wactawski-Wende, Jean PhD10

Editorial
Collapse Box

Abstract

Objective

Although joint symptoms are commonly reported after menopause, observational studies examining exogenous estrogen’s influence on joint symptoms provide mixed results. Against this background, estrogen-alone effects on joint symptoms were examined in post hoc analyses in the Women’s Health Initiative randomized, placebo-controlled, clinical trial.

Methods

A total of 10,739 postmenopausal women who have had a hysterectomy were randomized to receive daily oral conjugated equine estrogens (0.625 mg/d) or a matching placebo. The frequency and severity of joint pain and joint swelling were assessed by questionnaire in all participants at entry and on year 1, and in a 9.9% random subsample (n = 1,062) after years 3 and 6. Logistic regression models were used to compare the frequency and severity of symptoms by randomization group. Sensitivity analyses evaluated adherence influence on symptoms.

Results

At baseline, joint pain and joint swelling were closely comparable in the randomization groups (about 77% with joint pain and 40% with joint swelling). After 1 year, joint pain frequency was significantly lower in the estrogen-alone group compared with the placebo group (76.3% vs 79.2%, P = 0.001), as was joint pain severity, and the difference in pain between randomization groups persisted through year 3. However, joint swelling frequency was higher in the estrogen-alone group (42.1% vs 39.7%, P = 0.02). Adherence-adjusted analyses strengthen estrogen’s association with reduced joint pain but attenuate estrogen’s association with increased joint swelling.

Conclusions

The current findings suggest that estrogen-alone use in postmenopausal women results in a modest but sustained reduction in the frequency of joint pain.

© 2013 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.